---
title: "Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 | NUVB Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293514962.md"
description: "Nuvation Bio Inc. (NYSE: NUVB) announced it will host a conference call and webcast on August 6, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide business updates. Investors and the public are invited to register via the company's Investor Relations website or dial into the live call using the provided access code."
datetime: "2026-07-22T12:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293514962.md)
  - [en](https://longbridge.com/en/news/293514962.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293514962.md)
generator: "portal-rs"
---

# Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 | NUVB Stock News

, /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2026.

Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (U.S. toll-free) and enter access code 762246460. An archived recording will be available on Nuvation Bio's website for 90 days following the event.

**About Nuvation Bio**  
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. 

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc). 

**Media and Investor Contacts**

**Nuvation Bio Investor Contact**  
JR DeVita  
ir@nuvationbio.com

**Nuvation Bio Media Contact**  
Kaitlyn Nealy  
media@nuvationbio.com

SOURCE Nuvation Bio, Inc.

### Related Stocks

- [NUVB.US](https://longbridge.com/en/quote/NUVB.US.md)
- [NA.US](https://longbridge.com/en/quote/NA.US.md)
- [NUVB+.US](https://longbridge.com/en/quote/NUVB+.US.md)

## Related News & Research

- [NUVB: IBTROZI dominates ROS1 with best-in-class efficacy, while safusidenib advances across glioma subtypes](https://longbridge.com/en/news/298637147.md)
- [Nuvation Bio (NUVB) Gains Fast Track Backing As Fair Value Stays In Focus](https://longbridge.com/en/news/296701962.md)
- [Telkom Indonesia releases transcript of 2026 Public Expose Live](https://longbridge.com/en/news/298464216.md)
- [Radana Bhaskara Finance releases transcript of 2026 annual public expose live event](https://longbridge.com/en/news/298536299.md)
- [DarkPulse CEO Dennis O’Leary gives business update in X livestream](https://longbridge.com/en/news/298353682.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**